Evidence map›Paper›PMID 40841208›Full record

ArticleTrends in biotechnology2026

Strengthening the competitiveness of EU in vitro biotechnologies.

Milena Mennecozzi, Monica Piergiovanni, Lucia Selfa Aspiroz, Maurice Whelan

Abstract read
In one paragraph

Article in Trends in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Milena MennecozziEuropean Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: milena.mennecozzi@ec.europa.eu.
Monica PiergiovanniEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Lucia Selfa AspirozEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Maurice WhelanEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The EU has been a leader in research and development of in vitro biotechnology (IVB), such as human 3D cell and tissue models used in disease research and drug development. However, it is struggling to convert scientific discoveries into business creation and competitiveness within a rapidly growing international market.

Indexed as

BiotechnologyEconomic CompetitionEuropean UnionHumansbiotechnologyEU competitivenessindustrial ecosystemin vitromarket analysis

Identifiers

PMID40841208
PMCPMC12884251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.